Indian Pharma companies not responding to overcharging enquiry
In India, even after four months of receiving overcharging notices from the department of pharmaceuticals (DoP), not even one of the 500-odd pharma companies have responded to the charges, reports the local Hindustan Times.
The DoP had sent the notices to the companies through the Indian Drug Manufacturers’ Association (IDMA), the industry body of Indian companies, and the Organisation of Pharmaceutical Producers of India (OPPI), which represents global pharma companies in India.
“After that, we also issued a public notice asking the companies to submit the details within 30 days but not even a single firm has replied,” Raja Sekhar Vundru, joint secretary of DoP, told Hindustan Times.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze